

Memo

5621 00 JUN -1 14:40

To: Commissioner of Food and Drugs, Dockets Management Branch
From: Schumarry Chao, MD, MBA *Schumarry Chao*
Date: 05/31/00
Re: Docket No 00N-1256

Notice of Participation

This memo serves as my notice of participation. In accordance with the instructions received, I submit the following:

Name: Dr. Schumarry Chao, MD, MBA
Address: 10680 Treena St., 6th Floor
Telephone #: 858.790.6355
Affiliation: MedImpact Healthcare Systems, Inc.
Availability: Available only on June 28, 2000
Sponsor: MedImpact Healthcare Systems, Inc.

Presentation Summary:

With the conversion of major therapeutic drug classes to OTC, access to patient aggregate drug profiles and the ability to intervene to minimize drug interactions will be lost. MedImpact, as a pharmacy benefits company who prides itself on capitalizing on leading edge information technology to support the appropriate delivery of pharmaceuticals to optimize clinical outcome, we have concerns regarding the potentially adverse effect this may have on the quality of patient care. This is particularly disturbing in light of the recent study from the Institute of Health regarding the number of deaths from adverse reactions from drugs.

Approximate time of summary: 5 – 10 minutes

00N - 1256

APE 44